Search results for "myasthenic syndrome"

showing 4 items of 4 documents

Molecular characterization of congenital myasthenic syndromes in Spain.

2017

Congenital myasthenic syndromes (CMS) are a heterogeneous group of genetic disorders, all of which impair neuromuscular transmission. Epidemiological data and frequencies of gene mutations are scarce in the literature. Here we describe the molecular genetic and clinical findings of sixty-four genetically confirmed CMS patients from Spain. Thirty-six mutations in the CHRNE, RAPSN, COLQ, GFPT1, DOK7, CHRNG, GMPPB, CHAT, CHRNA1, and CHRNB1 genes were identified in our patients, with five of them not reported so far.. These data provide an overview on the relative frequencies of the different CMS subtypes in a large Spanish population. CHRNE mutations are the most common cause of CMS in Spain, …

AdultMale0301 basic medicineSlow-channel syndromeAdolescentNeuromuscular transmissionGMPPBGene mutationCOLQCongenital myasthenic syndromeYoung Adult03 medical and health sciences0302 clinical medicineDOK7COLQmedicineHumansCHRNECHRNEGeneGenetics (clinical)health care economics and organizationsMyasthenic Syndromes CongenitalGeneticsbiologyRAPSNMiddle AgedCongenital myasthenic syndromemedicine.diseasePhenotype3. Good healthGenetic mutationsRAPSN030104 developmental biologyGFPT1NeurologySpainPediatrics Perinatology and Child Healthbiology.proteinFemaleNeurology (clinical)030217 neurology & neurosurgery
researchProduct

Plectin-related scapuloperoneal myopathy with treatment-responsive myasthenic syndrome

2020

AdultMalePathologymedicine.medical_specialtyHistologymyasthenic syndromeMuskel- und KnochenstoffwechselPathology and Forensic MedicineEpidermolysis bullosa simplexAdrenergic AgentsPhysiology (medical)medicineHumansMuscular dystrophyFrameshift MutationEphedrineMyasthenic Syndromes Congenitalbusiness.industryPlectin-relatedPlectinmedicine.diseaseScapuloperoneal myopathyMuscular Dystrophy Emery-Dreifusstreatment-responsiveNeurologyPlectinNeurology (clinical)business
researchProduct

Five years experience on 3,4-diaminopyridine phosphate in Lambert-Eaton syndrome: Case reports

2017

Abstract Rationale: To report our experience on 7 patients (4 males and 3 females), affected by nonparaneoplastic Lambert–Eaton myasthenic syndrome, treated with 3,4-diaminopyridine phosphate (3,4-DAPP) either alone or in combination with other immunosuppressants or steroids. Patient concerns: Patients have been evaluated at specific timepoints (ie, baseline and last 5 year follow-up), with neurological examination, autoantibodies against presynaptic voltage-gated Cav2.1 (P/Q type) calcium ion channel (VGCC) dosage, neurophysiological evaluation focusing on the increased amplitude of the compound muscle action potential (cMAP) after maximum voluntary effort, quantitative myasthenia gravis (…

AdultMalemedicine.medical_specialtyAzathioprineNeurological examination030204 cardiovascular system & hematologySeverity of Illness Index5300nonparaneoplastic-Lambert–Eaton myasthenic syndrome03 medical and health sciences0302 clinical medicinePrednisoneInternal medicineSeverity of illnessActivities of Daily LivingAzathioprinemedicineHumansMuscle StrengthClinical Case Report4-AminopyridineAdverse effect34-diaminopyridine phosphate; nonparaneoplastic-Lambert-Eaton myasthenic syndrome; 4-Aminopyridine; Activities of Daily Living; Adult; Azathioprine; Drug Therapy Combination; Female; Humans; Immunosuppressive Agents; Lambert-Eaton Myasthenic Syndrome; Male; Middle Aged; Muscle Strength; Prednisone; Severity of Illness Index; Treatment Outcome; Medicine (all)medicine.diagnostic_testbusiness.industry34-diaminopyridine phosphateGeneral MedicineMiddle Agedmedicine.diseaseMyasthenia gravisLambert-Eaton Myasthenic SyndromeTreatment OutcomeConcomitantPrednisoneDrug Therapy CombinationFemaleAmifampridinebusinessLambert-Eaton myasthenic syndrome030217 neurology & neurosurgeryImmunosuppressive Agentsmedicine.drugResearch Article
researchProduct

Severe congenital myasthenic syndrome due to homozygosity of the 1293insG ε-acetylcholine receptor subunit mutation

2000

Recently, a congenital myasthenic syndrome (CMS) with end-plate acetylcholine receptor (AChR) deficiency due to missense mutations in the genes for the AChR subunit was described. The first observed patient with this CMS was heteroallelic for the two epsilon-AChR subunit mutations epsilon1101insT and epsilon1293insG. This patient had only a moderate phenotype with mild muscle weakness and abnormal fatigue. We have now found homozygosity for the epsilon1293insG mutation in a severely affected CMS patient, who lost the ability to walk in midchildhood and shows profound weakness and muscle wasting. Our observation allows a genotype-phenotype correlation illustrating how differences in the AChR…

MutationWeaknessmedicine.medical_specialtyNonsense mutationHaplotypeBiologyCongenital myasthenic syndromemedicine.disease_causemedicine.diseaseMyasthenia gravisEndocrinologyNeurologyInternal medicineImmunologymedicineMissense mutationNeurology (clinical)medicine.symptomAcetylcholine receptorAnnals of Neurology
researchProduct